Faslodex 250mg Injection contains fulvestrant, a selective estrogen receptor degrader used primarily in the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women. Fulvestrant works by binding to estrogen receptors, blocking the effects of estrogen, and promoting receptor degradation, thereby inhibiting the growth of estrogen-dependent cancer cells. Administered as an intramuscular injection, Faslodex is typically given once a month, with an initial loading dose regimen to achieve effective drug levels quickly. It is often prescribed for patients who have experienced disease progression following anti-estrogen therapy such as tamoxifen or aromatase inhibitors. Common side effects include injection site reactions, nausea, fatigue, hot flashes, and headache, while more serious adverse effects may involve liver function abnormalities and allergic reactions. Patients receiving Faslodex should be monitored regularly for liver enzymes and overall response to therapy. This medication should be used under the supervision of an oncologist experienced in breast cancer management. Faslodex offers a targeted hormonal treatment option that can improve progression-free survival and quality of life in women with advanced breast cancer resistant to other hormonal therapies.